K. Burk

20 papers receiving 288 citations

Peers

K. Burk
Comparison fields: 5 of 52
  • Cancer Research 81
  • Pulmonary and Respiratory Medicine 118
  • Molecular Biology 210
  • Oncology 77
  • Biomaterials 36
Replace Fumiki Asanuma with:
Fumiki Asanuma Japan
Salvatore Parisi Italy
Ho Young Lim South Korea
Jindong Sheng China
Tokushi Tachiwada Japan
Beverly Spicer United States
Wenkai Zhu China
Christine Buquet-Fagot France
P Hinnen Netherlands
K. Burk relative to Fumiki Asanuma Japan Fumiki Asanuma's profile →
Citations per field
00.5×2.6×
Fumiki Asanuma · 1×
Citations per year

Countries citing papers authored by K. Burk

Since Specialization
Citations

This map shows the geographic impact of K. Burk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Burk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Burk more than expected).

Fields of papers citing papers by K. Burk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Burk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Burk. The network helps show where K. Burk may publish in the future.

Co-authors

The 25 scholars most cited alongside K. Burk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with K. Burk Line = papers co-authored together K. Burk links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2007104
2 200658
3 199827
4 199018
5 200617
6 199616
7 199016
8 199413
9
Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
19898
10 19925
11 19943
12
Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up.
19893
13 19942
14
Weekly chemotherapeutic regimen in metastatic prostate cancer.
19892
15
Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly.
19872
16
Tur vs TUR plus adriamycin in patients with superficial bladder cancer--a five-year follow-up.
19891
17 19951
18 20061
19 20061
20 20071

About K. Burk

K. Burk is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Surgery and Cardiology and Cardiovascular Medicine, having authored 22 papers that have together received 299 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Bladder and Urothelial Cancer Treatments (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Toxin Mechanisms and Immunotoxins (3 papers), Cancer therapeutics and mechanisms (2 papers), Cancer, Lipids, and Metabolism (2 papers), Melanoma and MAPK Pathways (2 papers) and Chemotherapy-related skin toxicity (2 papers). The work is most often cited by research in Cancer Research (81 citations), Pulmonary and Respiratory Medicine (118 citations), Molecular Biology (210 citations), Oncology (77 citations) and Biomaterials (36 citations). K. Burk has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Cezary Szczylik, Urban Scheuring, Sylvie Négrier, Michael Staehler, Thomas E. Hutson, Bernard Escudier, Frédéric Rolland, Ronald M. Bukowski, Tomasz Demkow and K. Mross. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer Chemotherapy and Pharmacology, Journal of Emergency Medicine and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact